reference/32935522

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/32935522

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	1145
issn	1527-7755 0732-183X
issueIdentifier	9
pageRange	1140-1145
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	1140
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_56ae3572be89197ba476d17f2c2283d2 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_504ff0f3d35a152e65fae65696bb0302
bibliographicCitation	Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, Savvides P, Romkes M. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011 Mar 20;29(9):1140–5. PMID: 21343546; PMCID: PMC3083869.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e27f2af2b2e816869fcedcdfdc49db5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1be1e912f0494bae52e9aa5f01354027 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b9c60d7c0849f34675c17ad825b8755 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_21b2581a290483e275d20b065f0069b4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c2a16ba7d131a0fbca07d2d75d93cfa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3d9f4060faf32a0f27a8a52f6364250e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_94fa7867d658478cd70a37cd82501484 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e1361121f697c346c1b3699023225ceb
date	2011-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1200/jco.2010.33.3591 https://pubmed.ncbi.nlm.nih.gov/PMC3083869 https://pubmed.ncbi.nlm.nih.gov/21343546
isPartOf	https://portal.issn.org/resource/ISSN/0732-183X https://portal.issn.org/resource/ISSN/1527-7755 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
discusses	http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0021454 http://id.nlm.nih.gov/mesh/M0443627 http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0137645 http://id.nlm.nih.gov/mesh/M0009376 http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M0441463 http://id.nlm.nih.gov/mesh/M0356369 http://id.nlm.nih.gov/mesh/M0009679
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D002294Q000188 http://id.nlm.nih.gov/mesh/D006258Q000188 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D009364Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D002294Q000235 http://id.nlm.nih.gov/mesh/D006147Q000031 http://id.nlm.nih.gov/mesh/D000068258 http://id.nlm.nih.gov/mesh/D012074 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D009364Q000235 http://id.nlm.nih.gov/mesh/D006258Q000473 http://id.nlm.nih.gov/mesh/D005971Q000008 http://id.nlm.nih.gov/mesh/D042965Q000235 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D013940Q000235 http://id.nlm.nih.gov/mesh/D006147Q000008 http://id.nlm.nih.gov/mesh/D000068437 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D015996 http://id.nlm.nih.gov/mesh/D006258Q000235 http://id.nlm.nih.gov/mesh/D061067 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D042461Q000235 http://id.nlm.nih.gov/mesh/D000911Q000008 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D002294Q000556 http://id.nlm.nih.gov/mesh/D009364Q000473 http://id.nlm.nih.gov/mesh/D011110Q000235
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_1.5.1.20 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7905 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6651 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10308 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7969 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398658 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f711b441c08d32e3c24e3fd3df4a2c3d http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_714b3f52d8149c3277181d9513b93112 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.1.1.45

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128866026 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129439837 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127946097

Total number of triples: 90.